ATE449850T1 - Mutanten von flt3-l und ihre verwendungen - Google Patents

Mutanten von flt3-l und ihre verwendungen

Info

Publication number: ATE449850T1
Authority: AT; Austria
Prior art keywords: flt3; mutant polypeptides; disclosed; nucleic acids; ligand
Prior art date: 1998-07-02

Application number

AT99930657T

Other languages

English (en)

Inventor

Thomas Graddis

Jeffrey Mcgrew

Original Assignee

Celldex Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-02

Filing date

1999-06-25

Publication date

2009-12-15

1999-06-25 Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc

2009-12-15 Application granted granted Critical

2009-12-15 Publication of ATE449850T1 publication Critical patent/ATE449850T1/de

Links

229920001184 polypeptide Polymers 0.000 abstract 4
108090000765 processed proteins & peptides Proteins 0.000 abstract 4
102000004196 processed proteins & peptides Human genes 0.000 abstract 4
238000000034 method Methods 0.000 abstract 3
102000039446 nucleic acids Human genes 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
150000007523 nucleic acids Chemical class 0.000 abstract 2
102100039064 Interleukin-3 Human genes 0.000 abstract 1
108010002386 Interleukin-3 Proteins 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
108700014844 flt3 ligand Proteins 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000003993 interaction Effects 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Crystallography & Structural Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT99930657T 1998-07-02 1999-06-25 Mutanten von flt3-l und ihre verwendungen ATE449850T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/109,100 US6291661B1 (en)	1998-07-02	1998-07-02	flt3-L mutants and method of use
PCT/US1999/014296 WO2000001823A2 (en)	1998-07-02	1999-06-25	Flt3-l mutants and methods of use

Publications (1)

Publication Number	Publication Date
ATE449850T1 true ATE449850T1 (de)	2009-12-15

Family

ID=22325768

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99930657T ATE449850T1 (de)	1998-07-02	1999-06-25	Mutanten von flt3-l und ihre verwendungen

Country Status (8)

Country	Link
US (2)	US6291661B1 (de)
EP (1)	EP1092030B1 (de)
AT (1)	ATE449850T1 (de)
AU (1)	AU767149B2 (de)
CA (1)	CA2332345A1 (de)
DE (1)	DE69941701D1 (de)
NZ (1)	NZ509576A (de)
WO (1)	WO2000001823A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6376067B1 (en) *	1998-12-21	2002-04-23	Mitsubishi Polyester Film, Llc	Silicone coated film with back side slip control coating and method of controlling slip of such film
US7345019B1 (en) *	1999-04-13	2008-03-18	The Kenneth S. Warren Institute, Inc.	Modulation of excitable tissue function by peripherally administered erythropoietin
GB9924981D0 (en) *	1999-10-21	1999-12-22	Univ Manchester	Gene therapy
ES2254408T4 (es) *	2000-04-25	2007-10-01	Immunex Corporation	Procedimiento de tratamiento de tumores usando terapia fotodinamica.
AU2002232447A1 (en) *	2000-11-02	2002-05-15	Immunex Corporation	Method of enhancing lymphocyte-mediated immune responses
US7767643B2 (en)	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) *	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1351707B9 (de) *	2001-01-09	2012-01-25	Baylor Research Institute	Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
US20030017529A1 (en) *	2001-06-27	2003-01-23	Applera Corporation	Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
US6797493B2 (en) *	2001-10-01	2004-09-28	Lee-Hwei K. Sun	Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
WO2003032728A2 (en) *	2001-10-19	2003-04-24	Creighton University	Methods for preventing or reversing asthma and compositions useful therefor
DE10158680B4 (de) *	2001-11-30	2004-04-08	Universitätsklinikum Hamburg-Eppendorf	Verfahren zur ex vivo-Expansion und -Differenzierung von multipotenten Stammzellen
MXPA04009394A (es) *	2002-03-26	2005-01-25	Inmunex Corp	Metodos para utilizar ligando flt3 en procedimientos de inmunizacion.
CA2488876A1 (en) *	2002-06-13	2003-12-24	Oregon Health & Science University	Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets
US20040254108A1 (en) *	2003-06-13	2004-12-16	Jing Ma	Preparation and application of anti-tumor bifunctional fusion proteins
US20050232931A1 (en) *	2003-06-13	2005-10-20	Oncomax Acquisition Corp.	Preparation and application of anti-tumor bifunctional fusion proteins
WO2005032467A2 (en) *	2003-09-29	2005-04-14	Warren Pharmaceuticals, Inc.	Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
DE102004019323A1 (de) *	2004-04-21	2005-11-10	Toximed Gmbh	Mit toxischen Substanzen beladene dendritische Zellen zur Behandlung von Nierenzellkarzinomen
WO2005113019A2 (en) *	2004-05-14	2005-12-01	University Of Louisville Research Foundation, Inc.	Methods for the treatment of autoimmune diseases
CN1993460A (zh) *	2004-07-12	2007-07-04	索林集团意大利有限公司	用于培养人细胞的装置和方法
EP1786474B1 (de) *	2004-08-12	2011-06-01	Cedars-Sinai Medical Center	Kombinierte gentherapie zur behandlung makroskopischer glioma
US20070048254A1 (en) *	2005-08-24	2007-03-01	Mirus Bio Corporation	Generation of dendritic cells
US8883493B2 (en) *	2007-01-30	2014-11-11	Cedars-Sinai Medical Center	Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
US8574567B2 (en) *	2007-05-03	2013-11-05	The Brigham And Women's Hospital, Inc.	Multipotent stem cells and uses thereof
EP2607477B1 (de)	2007-05-03	2020-09-23	The Brigham and Women's Hospital, Inc.	Multipotente stammzellen und ihre verwendung
DE102008061522A1 (de)	2008-12-10	2010-06-17	Biontech Ag	Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
US12539308B2 (en)	2018-01-08	2026-02-03	The Trustees Of The University Of Pennsylvania	Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
US11246908B2 (en)	2018-01-10	2022-02-15	The Johns Hopkins University	Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
US12123881B2 (en) *	2018-04-20	2024-10-22	Unm Rainforest Innovations	Rap1-Gtp, Rac1-GTP and FMS-like tyrosine kinase 3 ligand (FLT3-L) as biomarkers for early detection of sepsis
US20190328785A1 (en) *	2018-04-30	2019-10-31	The Board Of Regents Of The University Of Oklahoma	Flt3-binding chimeric antigen receptors, cells, and uses thereof
WO2020198659A1 (en) *	2019-03-28	2020-10-01	Orionis Biosciences, Inc.	Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins
US20220177550A1 (en) *	2019-03-28	2022-06-09	Orionis Biosciences, Inc.	Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)
WO2020263830A1 (en) *	2019-06-25	2020-12-30	Gilead Sciences, Inc.	Flt3l-fc fusion proteins and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5073627A (en) *	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
US5554512A (en)	1993-05-24	1996-09-10	Immunex Corporation	Ligands for flt3 receptors
CZ307995A3 (en)	1993-05-24	1996-10-16	Immunex Corp	Ligands for flt3 receptors
RO120579B1 (ro)	1995-10-04	2006-04-28	Immunex Corporation	Utilizarea ligandului flt3
US5885962A (en)	1996-04-05	1999-03-23	Amgen Inc.	Stem cell factor analog compositions and method
US6660257B1 (en)	1996-10-25	2003-12-09	Pharmacia Corporation	Circular permuteins of flt3 ligand

1998
- 1998-07-02 US US09/109,100 patent/US6291661B1/en not_active Expired - Fee Related
1999
- 1999-06-25 AT AT99930657T patent/ATE449850T1/de not_active IP Right Cessation
- 1999-06-25 AU AU47148/99A patent/AU767149B2/en not_active Ceased
- 1999-06-25 DE DE69941701T patent/DE69941701D1/de not_active Expired - Lifetime
- 1999-06-25 NZ NZ509576A patent/NZ509576A/en not_active IP Right Cessation
- 1999-06-25 CA CA002332345A patent/CA2332345A1/en not_active Abandoned
- 1999-06-25 EP EP99930657A patent/EP1092030B1/de not_active Expired - Lifetime
- 1999-06-25 WO PCT/US1999/014296 patent/WO2000001823A2/en not_active Ceased
2001
- 2001-07-16 US US09/904,536 patent/US7067118B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7067118B2 (en)	2006-06-27
NZ509576A (en)	2003-12-19
AU4714899A (en)	2000-01-24
WO2000001823A2 (en)	2000-01-13
AU767149B2 (en)	2003-10-30
WO2000001823A3 (en)	2000-08-03
EP1092030A2 (de)	2001-04-18
EP1092030B1 (de)	2009-11-25
US6291661B1 (en)	2001-09-18
CA2332345A1 (en)	2000-01-13
US20020111475A1 (en)	2002-08-15
DE69941701D1 (de)	2010-01-07

Legal Events

Date	Code	Title	Description
2010-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE449850T1 (de)	2009-12-15	Mutanten von flt3-l und ihre verwendungen
WO1999053061A3 (en)	2000-03-23	Tumor associated nucleic acids and uses therefor
DK0917571T3 (da)	2005-03-14	Hidtil ukendt agoutirelateret gen
CA2232727A1 (en)	1997-03-27	Novel variants of green fluorescent protein, gfp
NZ527182A (en)	2004-06-25	Neisseria meningitidis antigens and compositions
EP1464706A3 (de)	2004-11-03	HEK5, HEK7, HEK8, HEK11, EPH-ähnliche Protein-Tyrosinkinase-Rezeptoren
DE68929043D1 (de)	1999-09-09	Für androgen-rezeptor-protein kodierende dna
ATE298365T1 (de)	2005-07-15	Hydantoinase-varianten mit verbesserten eigenschaften und ihre anwendung zur produktion von aminosäuren
DE3585953D1 (de)	1992-06-04	Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
HU9601448D0 (en)	1996-07-29	Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
IL115792A0 (en)	1996-01-19	Al-1 neurothophic factor
DE3676683D1 (de)	1991-02-07	Mischung von derivaten von aminosaeuren, verfahren zur herstellung der mischung und verwendung der mischung zur mengenbestimmung der aminosaeuren.
DE3587875D1 (de)	1994-08-11	Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
CA2170515A1 (en)	1995-03-09	Nucleotide sequences for novel protein tyrosine phosphatases
GR3036782T3 (en)	2002-01-31	Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
DE69737651D1 (de)	2007-06-06	Cortistatin: neuropeptide, zusammensetzungen und methoden
DK0562508T3 (da)	1999-03-29	Nyt knogle-relateret protein OSF-2, fremgangsmåde til dets fremstilling samt farmaceutisk præparat med indhold deraf
ATE314477T1 (de)	2006-01-15	An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung
DE68917154D1 (de)	1994-09-01	C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
EP1203775A3 (de)	2004-02-04	Chemoattraktion-auslösender Faktor aus Lymphozyten und dessen Verwendung
DE59005821D1 (de)	1994-06-30	Verfahren zur Herstellung von L-Isoleucin und dafür geeignete Mikroorganismen und rekombinante DNA.
EP0816504A3 (de)	1999-01-07	Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
SE9602822D0 (sv)	1996-07-19	New receptor
DE69934017D1 (de)	2006-12-28	2,6-beta-d-fruktanhydrolase enzym und verfahren zu dessen verwendung
ATE332974T1 (de)	2006-08-15	Il-1/tnf-alpha-activated kinase (itak), und verfahren zu ihrer herstellung und verwendung